Medical and Pharmaceutical Translation: A Complete Guide

This guide is for medical device manufacturers, pharmaceutical and biotech companies, contract research organisations, healthcare providers and patients who need health-related content in another language. It explains which rules decide the language of medical documents in the UK and EU, what each type of medical translation involves, and how to organise it safely.

Each section summarises a topic and links to a detailed article. Use the guide as a map: start with the section that matches your document, then follow the link for the full requirements.

What is medical and pharmaceutical translation?

Medical translation is the translation of content about health, diagnosis, treatment and medical products. Pharmaceutical translation is the part that concerns medicines, from development and clinical trials to licensing, packaging and safety monitoring. In practice the two overlap, and the same agency or team often handles both.

What makes the field distinctive is the combination of risk and regulation. A mistranslated dose, warning or consent statement can harm a patient. Many documents are also reviewed by regulators, ethics committees or notified bodies, who check that the translation matches approved content and suits its reader.

Medical translation serves several audiences, and each one needs a different style:

• Regulators and assessors, who read technical files, protocols and safety reports.
• Healthcare professionals, who use instructions for use, summaries of product characteristics and clinical letters.
• Patients and the public, who read leaflets, consent forms, questionnaires and lay summaries.

Which rules decide the language of medical documents?

In the EU, the main regulations set the principle that information must be in a language the reader understands, and leave each Member State to specify which languages apply. In the UK, legislation requires English for medicine labels and leaflets and, in Great Britain, for device labelling. The table summarises the main rules.

The common thread is comprehension. The EU MDR, for example, requires instructions for use to be "written in terms readily understood by the intended user". A translation that is technically correct but unreadable for its audience can still fail the requirement.

Medical devices: labels, instructions for use and the EU MDR

Medical device translation covers labels, instructions for use, implant cards, software text, declarations of conformity and field safety notices. The EU Medical Device Regulation 2017/745 sets the language rule in Article 10(11):

"Manufacturers shall ensure that the device is accompanied by the information set out in Section 23 of Annex I in an official Union language(s) determined by the Member State in which the device is made available to the user or patient." (Regulation (EU) 2017/745, Article 10(11))

Our article on EU MDR language requirements for labels and instructions for use explains which device documents need translating, how the IVDR differs for self-tests, when electronic instructions for use are permitted, and the English-language rule in Great Britain. It also includes a step-by-step plan for building a language matrix by country.

Two points are easy to miss. First, the MDR's language obligations reach beyond the IFU to implant cards, the EU declaration of conformity and field safety notices. Second, switching to electronic instructions for use does not avoid translation: under Implementing Regulation (EU) 2021/2226, e-IFUs are limited to certain devices for professional users, must be published in the language set by the Member State, and paper copies must be supplied within 7 calendar days of a request.

Medicines: patient information leaflets and product information

Medicine translation centres on the product information: the summary of product characteristics for professionals, the labelling, and the patient information leaflet. In the UK, the MHRA approves only the English leaflet, and permits translations into other languages in common use if the information is identical.

For medicines authorised through the EU centralised procedure, EMA's linguistic review process requires translations into all EU languages by Day 215, at the latest 5 days after the CHMP opinion. Member States review them between Day 215 and Day 229. EMA's QRD templates, published in English and 25 other languages, fix the standard headings and statements that translations must follow.

Leaflet translation is also a writing task. The MHRA's guidance on patient information leaflets says content "will need to be translated into colloquial English for the patient", and the same principle applies in every target language: patients need everyday words, short sentences and unambiguous dosing instructions.

Our guide to patient information leaflet translation under MHRA and EMA requirements covers the UK English rule, Northern Ireland packs, QRD templates, user testing and a practical workflow for meeting the EMA timetable.

Clinical research: trial documents, outcome measures and back translation

Clinical research generates some of the largest medical translation projects, because multinational trials need documents for regulators, sites and participants in many languages at once. Three articles cover this area.

Clinical trial document translation

Clinical trial document translation: what sponsors need to know explains which documents need translating, what EU Clinical Trials Regulation 536/2014 says about dossier languages, consent information and investigational product labels, and the rules on lay summaries. It also notes that new UK clinical trials regulations came into force on 28 April 2026.

Linguistic validation of patient-reported outcomes

Questionnaires that patients complete, such as symptom diaries and quality-of-life scales, need more than translation. What is linguistic validation for patient-reported outcomes? walks through the ten ISPOR steps, cognitive debriefing with 5 to 8 patients per language, and what FDA guidance expects sponsors to document.

Back translation

Back translation, where an independent translator translates a text back into the source language for comparison, is often requested by sponsors and ethics committees. Back translation explained shows what the method reveals, what it misses, and how to run one properly.

Safety reporting: pharmacovigilance translation

Pharmacovigilance translation turns adverse event reports and safety literature into English for assessment and reporting. Under GVP Module VI, serious valid individual case safety reports must be submitted within 15 days and non-serious ones within 90 days of receipt, and translation time counts against those deadlines.

Our article on pharmacovigilance translation of adverse event reports explains the EU language rules for case reports, the role of the reporter's verbatim text, MedDRA coding considerations and how to build a workflow that meets day-zero obligations.

Patients and healthcare providers: medical records and NHS translation

Patients need medical translation too, especially when they travel for treatment, claim on insurance or move between health systems. NHS England's guidance for commissioners on interpreting and translation in primary care sets expectations for the NHS side:

"Documents translated for the benefit of patients must be translated by competent and appropriately trained translators and not by practice staff." (NHS England, Guidance for commissioners: Interpreting and Translation Services in Primary Care)

Translating medical records for treatment or insurance abroad explains which records to translate, how to obtain copies through a subject access request, what to ask insurers about certification, and how to protect health data. For spoken communication in clinics and hospitals, see our separate guide to working with interpreters in healthcare settings.

Timing matters for patients as much as for companies. The Information Commissioner's Office says organisations usually have one month to respond to a subject access request, so anyone planning treatment abroad should request copies of their records well before they need the translation.

Quality and technology: expertise and machine translation

Two questions come up in almost every medical translation project: who should translate, and can software do it instead. Both have a direct impact on patient safety and regulatory acceptance.

Why subject-matter experts matter

Why medical translation needs subject-matter experts shows the errors that only medical knowledge prevents, from ambiguous abbreviations to decimal separators and the shift between professional and patient language. It ends with questions to ask any provider about translator background, review and terminology.

When not to use machine translation

Machine translation in healthcare: when not to use it reviews NHS guidance and clinical studies. One study of Google Translate for emergency department instructions found the overall meaning was retained in 82.5% of translations, with accuracy ranging from 94% in Spanish to 55% in Armenian. The article sets out where MT is unsafe, where it may be acceptable with oversight, and how to write a policy.

How to plan a medical translation project, and the mistakes to avoid

A medical translation project runs smoothly when scope, audience and regulatory requirements are settled before translation begins. The following steps apply to most document types:

1. Define the reader and the market for each document: professional or patient, and which countries.
2. Confirm the language rules with the relevant authority, notified body, ethics committee or receiving organisation.
3. Finalise and approve the source text, written in clear, translatable language.
4. Prepare reference material: glossaries, previous translations, regulatory templates and style guides.
5. Choose the method: translation with independent review, back translation, or full linguistic validation, depending on risk.
6. Check the final layout of labels, leaflets and forms in every language before release.
7. Keep records of translators, reviewers, versions and approvals for audits and inspections.

Regulator guidance and published studies point to the same recurring mistakes:

• Starting too late, for example after an EMA opinion, when the review window is only days long.
• Using bilingual staff or family members instead of trained translators, which NHS England guidance discourages.
• Relying on raw machine translation for dosing, consent or safety text.
• Losing version control, so that an outdated translation stays in use after the source changes.
• Ignoring data protection. Health information is special category data under UK GDPR and must be shared only through secure channels.

Matching the quality method to the risk

Not every medical document needs the same level of checking. Match the method to the consequences of an error:

For general advice on selecting a supplier, see our buyer's guide on how to choose a translation agency.

How TranslationWorks can help with medical and pharmaceutical translation

TranslationWorks is a UK-based translation agency that provides medical and pharmaceutical translation, including device labelling, patient information leaflets, clinical trial documents, safety reports and patient records, through native-speaking professional linguists in more than 150 languages. We work remotely with clients everywhere and have served more than 300 companies.

Our medical and pharmaceutical translation service uses human translation with independent review, supported by our wider translation services. TranslationWorks holds ISO 9001 and ISO 27001 registration and Cyber Essentials certification, which matters for confidential product and patient data. Request a free quote for medical translation and we will reply within 24 hours.